Ratings PharmaEssentia Corporation

Equities

6446

TW0006446008

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
428 ^TWD	+0.94%		-0.47%	+23.70%

May. 13	PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's profit outlook over the next few years is a strong asset.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 86.94 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PHARMAESSENTIA CORPORATION	+23.70%	4.37B	-
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	118B	B+
REGENERON PHARMACEUTICALS, INC.	+10.80%	106B	B+
BIONTECH SE	-10.84%	23.4B	B+
ARGENX SE	-1.69%	22.1B	B
GENMAB A/S	-10.23%	18.34B	A-
WUXI APPTEC CO., LTD.	-41.92%	16.59B	A-
BEIGENE, LTD.	-15.11%	15.97B	B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.03B	C+
SAREPTA THERAPEUTICS, INC.	+17.53%	11.67B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes